Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Period	Debt/Equity
2018-06-30	-2.82
2019-06-30	-2.39
2020-06-30	-2.34
2021-06-30	-2.15
2022-06-30	-0.22
2023-06-30	0.33
2024-06-30	0.39
2025-06-30	0.31

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MESO	$13.92	+1.72%	0.27M
3
4
5

Mesoblast Ltd (MESO) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Mesoblast Ltd Data in Excel

More MESO Financial Data